

AACR
SCIENTIFIC
ACHIEVEMENT
AWARDS
2025-2026






AACR SCIENTIFIC ACHIEVEMENT AWARDS **2025-2026**




For more information concerning AACR's Scientific Achievement Awards, including eligibility criteria and nomination deadlines, visit **AACR.org/SAA**.

A decorative graphic consisting of a network of nodes and lines. The nodes are represented by circles of varying sizes and colors, including green, yellow, and blue. The lines are thin and connect the nodes, creating a complex web-like structure. The graphic is positioned on the left side of the page, extending from the top left towards the bottom right.

Since 1961, the AACR has presented hundreds of Prizes, Awards, and Lectureships to recognize the scientific achievements of scientists, clinicians, and physician-scientists who have collectively made significant contributions to the understanding, diagnosis, prevention, and treatment of cancer.

The AACR honors these outstanding individuals for their extraordinary accomplishments and for embodying excellence in cancer research.




AACR AWARD FOR LIFETIME ACHIEVEMENT IN CANCER RESEARCH

James P. Allison, PhD, FAACR

Vice President for Immunobiology, Chair and Regental Professor,
Department of Immunology; Founding Director, James P Allison Institute;
The University of Texas MD Anderson Cancer Center, Houston, TX

For lifelong scientific achievements and transformative contributions to cancer research and patient care that have revolutionized cancer treatment and revitalized the cancer immunology field. Most notably, his pioneering discovery and development of immune checkpoint blockade immunotherapy, including the identification of CTLA-4 as a negative regulator of T-cell activation and the translation of this insight into a first-in-class therapy. Through these landmark contributions, as well as his scientific leadership in advancing the future of immuno-oncology, Dr. Allison has had an unparalleled impact on the cancer field, reshaping its scientific direction and improving the lives of patients worldwide.



AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN BASIC CANCER RESEARCH

Housheng Hansen He, PhD

Professor, Department of Medical Biophysics, University of Toronto;
Senior Scientist, Princess Margaret Cancer Centre, University Health
Network, Toronto, Ontario, Canada

For pioneering contributions to cancer epigenetics and RNA medicine, particularly in revealing how chromatin accessibility and epigenomic landscapes govern oncogenic transcription. Dr. He's landmark studies of FOXA1-androgen receptor networks, noncoding RNAs, and RNA modifications have transformed understanding of tumour progression, plasticity, and therapeutic resistance. By bridging functional genomics with clinical insight, his work has generated foundational resources and opened new avenues for RNA-based precision therapies.



AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN BLOOD CANCER RESEARCH

AWARD SUPPORTED BY ABBVIE

John F. DiPersio, MD, PhD

Professor of Medicine and Immunology & Pathology; Virginia E. and Sam J. Golman Professor in Medicine; Director, Center for Gene and Cellular Immunotherapy; Washington University School of Medicine, St. Louis, MO

For pioneering advances in leukemia and stem cell biology, including essential contributions to the development of the hematopoietic stem cell mobilizing agents plerixafor and motixafortide and for identifying JAK1/2 signaling in graft-versus-host disease, which led to the identification and approval of JAK inhibitors, including ruxolitinib. His discoveries defining clonal evolution in acute myeloid leukemia have transformed the understanding of relapse and most recently, have advanced novel CAR T and CAR-iNKT therapies for T-ALL and multiple myeloma, thereby expanding available treatment options and improving patient outcomes.



AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN CHEMISTRY IN CANCER RESEARCH

Cheryl H. Arrowsmith, PhD

Senior Scientist, Princess Margaret Cancer Centre, University Health Network; Chief Scientist, Structural Genomics Consortium, Toronto; Professor, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

For pioneering contributions to chemical biology and cancer epigenetics, including foundational studies defining the structure and function of chromatin-associated proteins that regulate gene expression in cancer. Dr. Arrowsmith's work has enabled the development of chemical probes targeting epigenetic regulators such as protein methyltransferases, methyl-lysine 'reader domains', bromodomains, and other chromatin-modifying enzymes, providing critical tools to interrogate cancer biology. Through her leadership of the Structural Genomics Consortium, she has advanced open science approaches that have accelerated the discovery of novel therapeutic targets and strategies in cancer.




AACR DANIEL D. VON HOFF AWARD FOR OUTSTANDING CONTRIBUTIONS TO EDUCATION AND TRAINING IN CANCER RESEARCH

Charles W.M. Roberts, MD, PhD, FAACR

Executive Vice President and Director, St. Jude Comprehensive Cancer Center; Member, Department of Oncology; Lillian R. Cannon Comprehensive Cancer Center Director Endowed Chair, St. Jude Children's Research Hospital, Memphis, TN

For outstanding leadership and dedication to the education and training of cancer researchers across the spectrum of childhood cancer research including basic, translational, clinical, and population sciences. Dr. Roberts' exceptional mentorship has guided numerous trainees toward successful and diverse careers as independent investigators, academic leaders, and innovators in the biomedical enterprise. Through visionary initiatives, including the creation of the global Science of Childhood Cancer seminar series and leadership of career development programs for early-stage investigators, he has expanded access to high-quality training and fostered a vibrant, collaborative community that is shaping the next generation of leaders in pediatric, adolescent, and young adult cancer research.



AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH

AWARD SUPPORTED BY AFLAC

Ben Ho Park, MD, PhD

Director, Vanderbilt-Ingram Cancer Center; Benjamin F. Byrd, Jr. Chair in Oncology; Professor of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN

For groundbreaking research that has transformed our understanding of breast cancer at both the molecular and clinical level. His work has defined how PI3K/AKT signaling becomes deregulated during tumor progression, providing critical insights into therapeutic resistance, invasion, and metastasis. Most notably, Dr. Park pioneered the use of cell-free DNA (cfDNA) as a minimally invasive biomarker, revolutionizing precision cancer medicine by enabling the detection of genetic mutations, monitoring of disease progression, and tracking of minimal residual disease in breast cancer patients, in turn making it possible to identify metastatic potential in early-stage patients before disease progression.



AACR DISTINGUISHED LECTURESHIP ON THE SCIENCE OF CANCER HEALTH DISPARITIES

John M. Carethers, MD, FAACR

Vice Chancellor for Health Sciences; Distinguished Professor of Medicine;
Adjunct Professor of Public Health, University of California San Diego,
San Diego, CA

For his seminal contributions to the understanding and reduction of cancer disparities in colorectal cancer patients resulting in improved clinical outcomes. Dr. Carethers identified a higher prevalence of Elevated Microsatellite Alterations at Selected Tetranucleotide repeats (EMAST), a form of microsatellite instability linked to poor outcomes in African Americans with colorectal cancer. His findings have since advanced global precision medicine, informed early screening recommendations, and shaped national policies to promote equitable cancer prevention and patient care.



AACR JAMES S. EWING-THELMA B. DUNN AWARD FOR OUTSTANDING ACHIEVEMENT IN PATHOLOGY IN CANCER RESEARCH

David Rimm, MD, PhD

Anthony N. Brady Professor of Pathology; Professor of Medicine (Oncology); Director, Quantitative Diagnostics in Anatomic Pathology (QDAP) lab; Director, Yale Pathology Tissue Services; Director, Physician Scientist Training Program in Pathology; Department of Pathology, Yale University School of Medicine, New Haven, CT

For pioneering innovation in quantitative biomarker science that has transformed cancer diagnostics and treatment. Dr. Rimm's invention of the fluorescence based Automated Quantitative Analysis (AQUA) platform has revolutionized immunohistochemistry by enabling precise and reproducible protein measurement in tissue specimens. His extensive work advancing multiplexed and computational imaging approaches, and his leadership in defining clinically relevant differences in PD L1 assays, HER2 assays and immune biomarkers using standardization and harmonization approaches have effectively shaped precision cancer medicine.



AACR MARGARET FOTI AWARD FOR LEADERSHIP AND EXTRAORDINARY ACHIEVEMENTS IN CANCER RESEARCH

Antoni Ribas, MD, PhD, FAACR

Professor of Medicine; Rosalyn R. Shostak Heyman and Hannah Kully Shostak Endowed Chair; Professor of Surgery; Professor of Molecular and Medical Pharmacology; Director, Parker Institute for Cancer Immunotherapy, University of California Los Angeles, Los Angeles, CA

For exceptional leadership and extraordinary achievements in cancer research, including pioneering contributions to melanoma biology and cancer immunotherapy that have been instrumental in the clinical development of pembrolizumab and other transformative therapies. His seminal research has accelerated progress in cancer treatment by defining mechanisms of response and resistance to immunotherapy and guiding the rational design of innovative combination therapy approaches. Through his sustained leadership in clinical and translational research and service to the cancer research community, Dr. Ribas has played a pivotal role in advancing modern cancer medicine and has made a profound impact on patients and the broader cancer research field.



AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH

*AWARD SUPPORTED BY BREAST CANCER RESEARCH
FOUNDATION*

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology, Dana-Farber Cancer Institute;
Associate Professor, Harvard Medical School, Boston, MA

For pioneering work dedicated to optimizing targeted therapies for HER2-positive breast cancer through innovative clinical trials. Specifically, Dr. Tolaney's APT trial demonstrated the efficacy of a less intensive regimen involving paclitaxel and trastuzumab for early-stage, node-negative disease, effectively transforming national and international clinical treatment guidelines. Her leadership in establishing biomarker-driven personalized therapy approaches for cancer, including the development of CDK4/6 inhibitors has significantly advanced care in both metastatic and adjuvant settings, shaping the future of precision oncology for breast cancer patients..



AACR TEAM SCIENCE AWARD

AWARD SUPPORTED BY LILLY

Cancer Dependency Map (DepMap) Team Broad Institute

TEAM LEADER

Francisca Vazquez, PhD

Director, Cancer Dependency Map, Broad Institute,
Cambridge, MA

TEAM MEMBERS

Jesse S. Boehm, PhD

Catarina Campbell, PhD

Glenn Cowley, PhD

Joshua M. Dempster, PhD

**Levi A. Garraway,
MD, PhD, FAACR**

Todd R. Golub, MD, FAACR

William C. Hahn, MD, PhD

James McFarland, PhD

Philip Montgomery, MS

David E. Root, PhD

Jennifer A. Roth, MBA, MA

William R. Sellers, MD, FAACR

**Yuen-Yi “Moony” Tseng,
PhD, MS**

Aviad Tsherniak, MS

Barbara A. Weir, PhD

For pioneering the systematic mapping of genetic dependencies across cancer cells, creating a comprehensive resource that reveals genes and pathways essential for tumor survival. By combining large-scale CRISPR functional genomic screens, drug response data, and multi-omic profiling, the Cancer Dependency Map team has uncovered lineage- and genotype- specific cancer vulnerabilities, including synthetic lethal dependencies such as WRN in microsatellite instability cancers and PRMT5 dependencies in cancers harboring MTAP deletions. Their work has transformed the discovery and prioritization of therapeutic targets and has become a foundational resource for cancer research and drug development worldwide.




AACR-AMERICAN CANCER SOCIETY AWARD FOR RESEARCH EXCELLENCE IN CANCER EPIDEMIOLOGY AND PREVENTION

AWARD SUPPORTED BY THE AMERICAN CANCER SOCIETY

Elizabeth A. Platz, ScD, MPH

Professor and Martin D. Abeloff, MD Scholar in Cancer Prevention, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health; Associate Director of Population Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

For her internationally recognized contributions to cancer epidemiology and translational research, including her fundamental advancement of the understanding of prostate cancer development, progression, and prevention. Dr. Platz pioneered evidence linking intraprostatic inflammation to prostate cancer risk, identified telomere length patterns as powerful prognostic biomarkers, and demonstrated protective associations between statin use, cholesterol levels, and disease lethality. Her work has also revealed digoxin as a novel preventive and therapeutic candidate. Through visionary leadership and multidisciplinary collaborations, Dr. Platz has effectively shaped modern strategies for prostate cancer control and population health.



AACR-CANCER RESEARCH INSTITUTE LLOYD J. OLD AWARD IN CANCER IMMUNOLOGY

AWARD SUPPORTED BY CANCER RESEARCH INSTITUTE

Kenneth M. Murphy, MD, PhD

Eugene Opie First Centennial Professor, Pathology and Immunology,
Washington University School of Medicine, St. Louis, MO

For pioneering discoveries defining the development and functional specialization of dendritic cell subsets that regulate adaptive immune responses. Dr. Murphy's research elucidated the transcriptional programs controlling dendritic cell lineage commitment, including the role of transcription factors such as BATF3 in the development of cross-presenting dendritic cells required for priming cytotoxic T cell responses. His work has advanced fundamental understanding of antigen presentation and immune regulation and has informed strategies to enhance antitumor immunity and cancer immunotherapy.



AACR-G.H.A. CLOWES AWARD FOR OUTSTANDING BASIC CANCER RESEARCH

AWARD SUPPORTED BY LILLY

Andrew P. Feinberg, MD, MPH

Bloomberg Distinguished Professor, Johns Hopkins University Schools of Medicine, Engineering, and Public Health; Director, Center for Epigenetics, Institute for Basic Biomedical Sciences, Baltimore, MD

For pioneering discoveries establishing the fundamental role of epigenetic alterations in cancer, including the identification of early widespread DNA methylation abnormalities and the role of genomic imprinting in tumor development. Dr. Feinberg's research demonstrated that large-scale epigenomic alterations, including global DNA hypomethylation and partially methylated domains, contribute to tumor initiation, progression, and cellular heterogeneity, leading to the concept of epigenetic plasticity as a driver of cancer evolution. His discoveries established the epigenome as a central driver of cancer biology, identified causal epigenetic mechanisms for cancer risk and progression, and laid the foundation for new approaches to cancer detection, prevention, and therapeutic intervention.



AACR-IRVING WEINSTEIN FOUNDATION DISTINGUISHED LECTURESHIP

AWARD SUPPORTED BY IRVING WEINSTEIN FOUNDATION

Dennis Lo, DM DPhil FRCP FRCPath FRS MAE

Vice-Chancellor and President; Li Ka Shing Professor of Medicine;
Professor of Chemical Pathology, Chinese University of Hong Kong,
Ma Liu Shui, Hong Kong, SAR

In recognition of his pioneering contributions to biomedical science including his seminal discovery of fetal DNA in maternal plasma, a breakthrough that revolutionized noninvasive prenatal testing and laid the foundation for the field of circulating free and tumor DNA. Dr. Lo was the first to identify cell-free fetal DNA and fetal epigenetic markers in maternal plasma, enabling safer and earlier prenatal diagnostics. Building on this discovery, Dr. Lo demonstrated that DNA released by tumors may be used for cancer screening, an insight that led to the development of circulating DNA-based tools for early cancer detection and screening. His visionary research continues to transform clinical practice and remains a cornerstone of precision medicine by shaping modern approaches to cancer diagnosis, treatment selection, and monitoring.




AACR-JOSEPH H. BURCHENAL AWARD FOR OUTSTANDING ACHIEVEMENT IN CLINICAL CANCER RESEARCH

Luis A. Diaz Jr., MD, FAACR

Head, Division of Solid Tumor Oncology; Grayer Family Chair, Memorial Sloan Kettering Cancer Center, New York, NY

For pioneering discoveries that have transformed cancer treatment through biomarker-driven immunotherapy, including demonstrating that tumors with mismatch repair deficiency and microsatellite instability are highly responsive to immune checkpoint blockade. Dr. Diaz has also advanced the use of circulating tumor DNA to detect minimal residual disease and led clinical trials of PD-1 blockade in mismatch repair-deficient cancers, including rectal cancer studies showing complete responses with immunotherapy alone. His work established defective DNA repair as a predictive biomarker for immunotherapy response and enabled the first tissue-agnostic approval of a cancer therapy based on a molecular signature.



AACR-MINORITIES IN CANCER RESEARCH JANE COOKE WRIGHT LECTURESHIP

AWARD SUPPORTED BY GILEAD AND KITE ONCOLOGY

Ahmedin M. Jemal, DVM, PhD

Senior Vice President, Surveillance, Prevention, & Health Equity Science, American Cancer Society; Adjunct Professor, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA

For pioneering contributions to cancer epidemiology that have advanced understanding of cancer incidence, mortality, and disparities through integrative analyses of population-based cancer surveillance systems. Dr. Jemal's research has quantified temporal and geographic trends in cancer burden using large-scale analyses of cancer registry, mortality, and risk factor data, identifying population-level determinants of cancer incidence, survival, and stage at diagnosis across diverse demographic groups. His work has provided critical evidence linking changes in risk factor exposure, screening uptake, and treatment advances to declines in cancer mortality and has informed strategies for cancer prevention, early detection, and population-level cancer control.



AACR-PRINCESS TAKAMATSU MEMORIAL LECTURESHIP

*AWARD SUPPORTED BY THE PRINCESS TAKAMATSU
CANCER RESEARCH FUND*

David C. Lyden, MD, PhD

Stavros S. Niarchos Professor of Pediatrics and Cell and Developmental Biology, Director of the Physician-Scientist Training Program, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY

For pioneering discoveries defining how primary tumors systemically promote metastasis through the formation of pre-metastatic niches in distant organs. Dr. Lyden's research demonstrated that tumor-derived extracellular vesicles and exomeres, together with bone marrow-derived progenitor cells, remodel distant microenvironments and determine organ-specific metastatic tropism. His work has advanced understanding of metastatic dissemination and revealed links between tumor-derived vesicles, cancer-associated thrombosis, and systemic effects of cancer.




AACR-ST. BALDRICK'S FOUNDATION AWARD FOR OUTSTANDING ACHIEVEMENT IN PEDIATRIC CANCER RESEARCH

AWARD SUPPORTED BY THE ST. BALDRICK'S FOUNDATION

Kimberly Stegmaier, MD, FAACR

Chair, Department of Pediatric Oncology, Dana-Farber Cancer Institute; David G. Nathan Professor of Pediatrics, Harvard Medical School; Associate Chief, Division of Hematology/Oncology, Boston Children's Hospital; Institute Member, Broad Institute, Boston, MA

For seminal contributions to pediatric precision oncology, including foundational genomic discoveries that defined the unique molecular landscape of childhood cancers and identified key drivers of fusion oncoprotein positive malignancies. Dr. Stegmaier's research uses systematic functional genomic screening and chemical biology strategies to identify critical dependencies in high-risk acute leukemias and pediatric solid tumors. Stegmaier has also successfully led "Big Science", such as the Pediatric Cancer Dependency Map, and leveraged this data toward conceptual advances, such as activation lethality, and the discovery of therapeutic targets. Her work has advanced understanding of leukemia and pediatric solid tumor biology and enabled new approaches for targeted therapy in these malignancies.



AACR-WAUN KI HONG AWARD FOR OUTSTANDING ACHIEVEMENT IN TRANSLATIONAL AND CLINICAL CANCER RESEARCH

AWARD SUPPORTED BY WAUN KI HONG ENDOWMENT FUND

Eliezer M. Van Allen, MD

Chandra Nohria Family Chair for AI in Cancer Research; Chief, Division of Population Sciences, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School, Boston, MA; Institute Member, Broad Institute of MIT and Harvard, Cambridge, MA

For pioneering discoveries advancing precision oncology through the integration of cancer genomics and computational biology to identify molecular determinants of therapeutic response and resistance. Dr. Van Allen's research has defined genomic mechanisms underlying resistance to targeted therapies, including BRAF inhibition in melanoma, and identified genomic features associated with response to immune checkpoint blockade through large-scale tumor sequencing and integrative genomic analyses. His work has advanced biomarker discovery and the use of genomic data to guide personalized cancer treatment.




AACR-WOMEN IN CANCER RESEARCH CHARLOTTE FRIEND LECTURESHIP

AWARD SUPPORTED BY GILEAD AND KITE ONCOLOGY

Maryellen L. Giger, PhD

A.N. Pritzker Distinguished Service Professor of Radiology,
The University of Chicago, Chicago, IL

For pioneering discoveries advancing cancer diagnosis through the development of computer-aided detection and machine learning methods for medical imaging and for her profound impact on advancing women in cancer research. Dr. Giger's research has established quantitative imaging and radiomics approaches that extract high-dimensional features from radiologic images to characterize tumor phenotype and predict cancer risk, diagnosis, and treatment response. A dedicated mentor and role model, she has guided more than 120 trainees and championed the careers of women scientists and clinicians, fostering a new generation of leaders in imaging and cancer research.



PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR EXTRAORDINARY ACHIEVEMENT IN CANCER RESEARCH

AWARD SUPPORTED BY THE PEZCOLLER FOUNDATION

Douglas R. Lowy, MD, FAACR

Chief, Laboratory of Cellular Oncology; NIH Distinguished Investigator; Head, Signaling and Oncogenesis Section; Principal Deputy Director, National Cancer Institute, National Institutes of Health, Bethesda, MD

John T. Schiller, PhD, FAACR

Chief, Section of Neoplastic Disease; Deputy Chief, Laboratory of Cellular Oncology; NIH Distinguished Investigator, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

For pioneering the molecular and immunologic foundations of Human Papilloma (HPV) vaccines, engineering virus-like particles for safe and effective immunization and driving their translation into global cancer prevention strategies that have dramatically reduced cervical and other HPV-related cancer incidence. Their discovery has transformed the cancer prevention field, saved millions of lives, and continues to inspire scientists to develop new cancer preventative vaccines..



AACR OUTSTANDING ACHIEVEMENT AWARD FOR SERVICE TO CANCER SCIENCE AND MEDICINE

David R. Parkinson, MD

Principal, Drug Development, Ellison Medical Institute, Los Angeles, CA

For extraordinary leadership and unwavering dedication to advancing lifesaving cancer therapeutics, strengthening national cancer research and regulatory initiatives, providing scientific and fiduciary oversight of AACR Project GENIE®, and spearheading major biopharmaceutical innovations including the development and implementation of imatinib (Gleevec), zoledronic acid (Zometa), letrozole (Femara), and panitumumab (Vectibix) that have and continue to transform cancer patient care.



AACR DISTINGUISHED PATIENT ADVOCACY AND ENGAGEMENT AWARD

Jill Feldman

Lung Cancer Patient and Advocate; Co-Founder, President EGFR Resisters,
Deerfield, IL

For extraordinary leadership, unwavering commitment, and transformative impact on the lung cancer patient advocacy community and the broader lung cancer research community.



**AACR JUNE L. BIEDLER PRIZE
FOR CANCER JOURNALISM
MAGAZINE CATEGORY**

Laurie Abraham

Freelance Journalist and Editor

New York Magazine

New York, NY

"My Colon"



**AACR JUNE L. BIEDLER PRIZE
FOR CANCER JOURNALISM
NEWSPAPER CATEGORY**

Carolyn Y. Johnson

Science Reporter
The Washington Post
Washington, DC

"NIH scientists have a cancer breakthrough. Layoffs are delaying it."



**AACR JUNE L. BIEDLER PRIZE
FOR CANCER JOURNALISM
ONLINE/MULTIMEDIA CATEGORY**

Robert Langreth

Senior Reporter
Bloomberg News
New York, NY

**Tanaz Meghjani,
MS, BA**

Data Journalist
Bloomberg News
New York, NY

Anna Edney

National Health
Care Reporter
Bloomberg News
New York, NY

"Cancer Capitalism"



AACR JUNE L. BIEDLER PRIZE FOR CANCER JOURNALISM **TELEVISION/RADIO/PODCASTS CATEGORY**

Jes Burns

Science Producer and Host,
“All Science. No Fiction.”
Oregon Public Broadcasting (OPB)
Portland, OR

Brooke Herbert

Cinematographer and Editor
Oregon Public Broadcasting (OPB)
Portland, OR

“Researchers in Oregon aim to slow down cancer by remotely cooking tumors”



**AACR JUNE L. BIEDLER PRIZE
FOR CANCER JOURNALISM
TELEVISION/RADIO/PODCASTS CATEGORY**

Cristin Severance

Documentary Producer
WRAL
Raleigh, NC

Dwayne Myers

Photojournalist
WRAL
Raleigh, NC

"Diagnosis Young: The New Face of Cancer in NC"

AACR SCIENTIFIC ACHIEVEMENT AWARD SUPPORTERS



**Irving Weinstein
Foundation**

**June L. Biedler
Endowment Fund**



**Waun Ki Hong
Endowment
Fund**



AACR SCIENTIFIC ACHIEVEMENT AWARD DESCRIPTIONS

AACR AWARD FOR LIFETIME ACHIEVEMENT IN CANCER RESEARCH

This award was established to honor individuals who have made significant fundamental contributions to cancer research, either through a single scientific discovery or a collective body of work, that must have had a lasting impact on the cancer field and must have demonstrated a lifetime commitment to progress against cancer.

AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN BASIC CANCER RESEARCH

This award recognizes an early-career investigator for meritorious achievements in basic cancer research. Candidates must have not yet reached 46 years of age at the time of the award presentation.

AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN BLOOD CANCER RESEARCH

AWARD SUPPORTED BY ABBVIE

This award recognizes an individual on the basis of their meritorious achievements and contributions to any aspect of blood cancer research.

AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN CHEMISTRY IN CANCER RESEARCH

This award is presented for outstanding, novel, and significant chemistry research that has led to important contributions in basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer, or the treatment of patients with cancer.



AACR DANIEL D. VON HOFF AWARD FOR OUTSTANDING CONTRIBUTIONS TO EDUCATION AND TRAINING IN CANCER RESEARCH

This award is intended to honor an individual in any subfield or sector of cancer research and cancer-related sciences who has contributed significantly to the education and training of cancer researchers and other professionals at all career levels, especially of early-career and early-stage investigators.

AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH

AWARD SUPPORTED BY AFLAC

This award recognizes outstanding science that has inspired, or has the potential to inspire, new perspectives on the etiology, diagnosis, treatment, or prevention of breast cancer.

AACR DISTINGUISHED LECTURESHIP ON THE SCIENCE OF CANCER HEALTH DISPARITIES

This award recognizes an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of cancer health disparities.

AACR JAMES S. EWING-THELMA B. DUNN AWARD FOR OUTSTANDING ACHIEVEMENT IN PATHOLOGY IN CANCER RESEARCH

This award, named for the AACR's first President (Ewing) and first female President (Dunn), both of who were pathologists, serves to recognize and celebrate pathologists who have significantly contributed to advancing cancer research, diagnosis, treatment, and prevention.



AACR MARGARET FOTI AWARD FOR LEADERSHIP AND EXTRAORDINARY ACHIEVEMENTS IN CANCER RESEARCH

This award recognizes a true champion of cancer research whose leadership and extraordinary achievements in cancer research have had a major impact on the field.

AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH

AWARD SUPPORTED BY BREAST CANCER RESEARCH FOUNDATION

This award recognizes an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer. Candidates must have not yet reached 50 years of age at the time of the award presentation.

AACR TEAM SCIENCE AWARD


AWARD SUPPORTED BY LILLY

This award recognizes an outstanding interdisciplinary research team for their innovative and meritorious science that has advanced or may advance our fundamental knowledge of cancer, or a team that has applied existing knowledge to advancing the detection, diagnosis, prevention, or treatment of cancer.

AACR-AMERICAN CANCER SOCIETY AWARD FOR RESEARCH EXCELLENCE IN CANCER EPIDEMIOLOGY AND PREVENTION

AWARD SUPPORTED BY THE AMERICAN CANCER SOCIETY

This award recognizes outstanding research accomplishments in cancer epidemiology, biomarkers, and prevention.



**AACR-CANCER RESEARCH INSTITUTE
LLOYD J. OLD AWARD IN CANCER
IMMUNOLOGY**

AWARD SUPPORTED BY CANCER RESEARCH INSTITUTE

This award recognizes an active scientist whose outstanding and innovative research has had a major impact on the cancer field and has the potential to stimulate new directions in cancer immunology.

**AACR-G.H.A. CLOWES AWARD FOR
OUTSTANDING BASIC CANCER RESEARCH**

AWARD SUPPORTED BY LILLY

This award is intended to recognize an individual who has made outstanding recent accomplishments in basic cancer research.

**AACR-IRVING WEINSTEIN FOUNDATION
DISTINGUISHED LECTURESHIP**

AWARD SUPPORTED BY IRVING WEINSTEIN FOUNDATION

This award acknowledges an individual whose outstanding personal innovation in science and whose position as a thought leader in fields relevant to cancer research has the potential to inspire creative thinking and new directions in cancer research. The recipient is selected by the AACR President.

**AACR-JOSEPH H. BURCHENAL AWARD FOR
OUTSTANDING ACHIEVEMENT IN CLINICAL
CANCER RESEARCH**

This award recognizes outstanding achievements in clinical cancer research.



AACR-MINORITIES IN CANCER RESEARCH JANE COOKE WRIGHT LECTURESHIP

AWARD SUPPORTED BY GILEAD AND KITE ONCOLOGY

This lectureship recognizes an outstanding scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of minority investigators in cancer research.

AACR-PRINCESS TAKAMATSU MEMORIAL LECTURESHIP

*AWARD SUPPORTED BY THE PRINCESS TAKAMATSU
CANCER RESEARCH FUND*

This award recognizes an individual scientist whose novel and significant work has had or may have a far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and who embodies the dedication of Princess Takamatsu to multinational collaborations.

AACR-ST. BALDRICK'S FOUNDATION AWARD FOR OUTSTANDING ACHIEVEMENT IN PEDIATRIC CANCER RESEARCH


AWARD SUPPORTED BY THE ST. BALDRICK'S FOUNDATION

This award recognizes an individual in any sector who has significantly contributed to any area of pediatric cancer research, resulting in the fundamental improvement of the understanding and/or treatment of pediatric cancer.

AACR-WAUN KI HONG AWARD FOR OUTSTANDING ACHIEVEMENT IN TRANSLATIONAL AND CLINICAL CANCER RESEARCH

AWARD SUPPORTED BY WAUN KI HONG ENDOWMENT FUND

This award recognizes a worthy cancer researcher who has conducted highly meritorious translational and clinical cancer research anywhere in the world and who has not yet reached 51 years of age at the time of the award presentation.



AACR-WOMEN IN CANCER RESEARCH CHARLOTTE FRIEND LECTURESHIP

AWARD SUPPORTED BY GILEAD AND KITE ONCOLOGY

This award is presented to an outstanding scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of women in science.

PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR EXTRAORDINARY ACHIEVEMENT IN CANCER RESEARCH

AWARD SUPPORTED BY THE PEZCOLLER FOUNDATION

The prestigious Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research was established in 1997 to recognize a scientist of international renown who has made a major scientific discovery in basic cancer research or who has made significant contributions to translational cancer research.

AACR JUNE L. BIEDLER PRIZE FOR CANCER JOURNALISM RECIPIENTS

This prize showcases outstanding examples of cancer journalism and recognizes individual professional journalists who have produced accurate, informative, and compelling stories that enhance the public's understanding of cancer, cancer research, cancer advocacy, or cancer policy.



For more information concerning AACR's Scientific Achievement Awards, including eligibility criteria, scan the QR code or visit **AACR.org/SAA**.

Call for Nominations Deadline:
June 30, 2026

The AACR logo features the letters 'AACR' in a bold, sans-serif font. The 'A', 'A', and 'C' are white, while the 'R' is a vibrant green. A thin white horizontal line is positioned below the letters.

AACR

American Association
for Cancer Research®

FINDING CURES TOGETHER®

615 Chestnut Street, 17th Floor
Philadelphia, PA 19106-4404
215-440-9300 | AACR.org